RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha.

Interferon-alpha (IFN-alpha) is a cytokine that is effective in the treatment of a variety of cancers, including non-melanoma skin cancers. The biologic responses of cells to IFN-alpha are pleiotropic and include growth suppression and immunomodulation. The potential direct effects of IFN-alpha on tumor cell populations are incompletely characterized. Our findings indicate that IFN-alpha can directly induce apoptosis (programmed cell death) in sensitive squamous cell skin cancer cell lines. Cell lines resistant to the cytotoxic effects of IFN-alpha showed no evidence of apoptosis induction. Transfection of IFN-alpha-sensitive cell lines with a bcl-2 expression vector conferred partial resistance to cell death induction by IFN-alpha. Our results indicate that the clinical efficacy of IFN-alpha may, in part, be related to the ability of this cytokine to induce apoptosis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app